View Older Stories

Jun 2, 2025 08:10AM BMO Capital Comments on Regeneron Pharma (REGN): 'COURAGE Data/Obesity License Move REGN Forward'

Jun 2, 2025 07:38AM Regeneron Pharma (REGN) PT Lowered at BMO Capital as 'Updated Model Reflects Conservatism'

May 30, 2025 09:21AM BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

Nov 1, 2024 09:12AM Regeneron Pharma (REGN) PT Lowered to $1,190 at BMO Capital

Sep 30, 2024 08:29AM BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

Sep 23, 2024 04:00PM BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

Sep 17, 2024 07:34AM BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

Sep 12, 2024 08:46AM BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

Jul 12, 2024 07:51AM BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

Jun 3, 2024 12:28PM BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

Aug 21, 2023 08:02AM Regeneron (REGN) gets its 'mojo back' after FDA approves Eylea HD

Aug 21, 2023 06:10AM Regeneron Pharma (REGN) PT Raised to $985 at BMO Capital

Aug 18, 2023 02:08PM US FDA approves Regeneron's ultra-rare blood disease drug

May 4, 2023 06:39AM Regeneron's Eylea drug sales hit by competition from 'new kid in town'

Sep 8, 2022 01:59PM Regeneron (REGN) Eylea News Removes a 'Key Overhang' says Analyst

Sep 8, 2022 10:37AM Regeneron Pharma (REGN) 'High-Dose Eylea Data Far Exceeds Expectations, Supporting Franchise' - BMO

Jun 24, 2022 10:59AM "See Interesting Upside Potential for REGN" - BMO Capital Reiterates Regeneron (REGN) at Outperform on NTLA Data

May 4, 2022 07:40AM BMO Capital Reiterates Outperform Rating, $780 Price Target on Regeneron Pharma (REGN), Awaits Key Data from Oncology Programs

Apr 19, 2022 08:48AM BMO Capital Reiterates Outperform Rating, $780 Price Target on Regeneron Pharma (REGN) Following Checkmate (CMPI) Acquisition

Mar 29, 2022 05:52AM BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

Feb 11, 2022 09:46AM BMO Capital Reiterates Regeneron Pharma (REGN) at Outperform, "Eylea Phase 2 Data Supportive of Likely Positive Phase 3"

Feb 4, 2022 03:04PM Regeneron (REGN) Results Highlight Strong Fundamentals, Focus Remains on Novel Product Readouts - BMO Capital

Nov 18, 2021 04:17PM BMO Capital Assumes Regeneron Pharma (REGN) at Outperform

Nov 4, 2021 05:50PM Regeneron Pharma (REGN) PT Raised to $710 at BMO Capital

Sep 20, 2021 01:49PM Regeneron Pharma (REGN) PT Raised to $706 at BMO Capital

Aug 5, 2021 03:58PM Regeneron Pharma (REGN) PT Raised to $669 at BMO Capital

Jan 25, 2021 12:32AM UPDATE: BMO Capital Upgrades Regeneron Pharma (REGN) to Outperform

Nov 5, 2019 03:43PM Regeneron Pharma (REGN) PT Raised to $352 at BMO Capital

Oct 8, 2019 12:24PM Novartis' Beovu Label a Positive for Regeneron Pharma (REGN) - BMO

Aug 7, 2019 08:14AM Regeneron Pharma (REGN) PT Lowered to $344 at BMO Capital

May 8, 2019 09:06AM Regeneron Pharma (REGN) PT Lowered to $375 at BMO Capital

Feb 7, 2019 07:48AM Regeneron Pharma (REGN) PT Raised to $412 at BMO Capital

Feb 6, 2019 03:25PM Regeneron Pharma (REGN) PT Raised to $410 at BMO Capital

Mar 12, 2018 09:30AM Pre-Open Movers 03/12: (OCLR) (ADMS) (MU) Higher; (ANTH) (SVRA) (ESPR) Lower (more...)

Jul 31, 2017 08:39AM Regeneron (REGN): Sanofi Weakness Could Pressure Shares - BMO

Jul 19, 2017 07:15AM Regeneron (REGN): Raising PT On High Enthusiasm For Dupixent - BMO

Jun 20, 2017 10:44AM BMO Capital Maintains Market Perform Rating & $421 PT on Regeneron (REGN); Novartis RTH258 Ph3 Data Highlights Long-Term Eylea Risk

May 5, 2017 09:32AM Regeneron Pharma (REGN) PT Raised to $421 at BMO Capital; 'Too Early to Make a Call on Dupixent Launch'

Mar 28, 2017 03:23PM Regeneron Pharma (REGN) PT Raised to $412 at BMO Capital Following Approval of Dupixent in Adult Atopic Dermatitis

Dec 20, 2016 06:13AM BMO Capital Starts Regeneron Pharma (REGN) at Market Perform

Jan 25, 2016 10:30AM Notable Analyst Rating Changes 1/25: (RSYS) (HD) (JBHT) Upgraded; (REGN) (TWTR) (WFM) Downgraded

Jul 27, 2015 07:18AM Regeneron Pharma (REGN) PT Raised to $494 at BMO Capital

Jun 10, 2015 07:48AM Regeneron (REGN) PRALUEN Panel Commentary Could Result in Narrower-Than-Expected Labeling, BMO Capital Says

Jun 9, 2015 07:05AM Regeneron (REGN) Halted Ahead of FDA Panel Review of Praluent

Jun 8, 2015 07:03AM Regeneron (REGN) PRALUENT Briefing Docs Positive But Risk to Labeling for Statin Intolerance, BMO Capital Says

Feb 17, 2015 10:43AM Notable Analyst Rating Changes 2/17: (SRPT) (MU) (CCG) Upgraded; (IMAX) (CVC) (JWN) Downgraded

Nov 19, 2014 12:04PM Streetinsider.com's Hot Lunchtime Reads 11/19: (FNMA) (CLF) (TSLA) (GLD)

Oct 17, 2014 02:40PM BMO Capital Lift PT on Regeneron (REGN) 33% Following New EYLEA Data

Jun 20, 2014 10:46AM Regeneron (REGN) Sinks on Talk of Trend of Switching Away from EYLEA

Feb 13, 2014 10:49AM Notable Analyst Rating Changes 02/13: (ANR) (ATHN) (NSPH) Upgraded; (DEPO) (REGN) (AEM) Downgraded

View Older Stories